JW SHINYAK CORPORATION
Financials
Valuation Metrics
JW SHINYAK CORPORATION's Market Cap is ₩1227B. At end of 2025 it was ₩1194B. Ranked #1072 of 2,405 in KR market (top 45%), #550 of 1,627 on KOSDAQ (top 34%), #125 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-11-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 122.72B KRW | KR#1,072/2,405 Sec#125/231 |
| Revenue | 84.61B KRW | KR#1,515/2,405 Sec#95/231 |
| Net Income | 10.22B KRW | KR#963/2,405 Sec#61/231 |
| Total Assets | 61.91B KRW | KR#2,080/2,405 Sec#181/231 |
| Net Assets | 40.74B KRW | KR#2,028/2,405 Sec#178/231 |
| Employees | 188 | KR#1,143/2,405 Sec#94/231 |
| Value | ||
| P/E | 11.95x | KR#989/2,405 Sec#56/231 |
| P/B | 3.00x | KR#2,138/2,405 Sec#173/231 |
| P/S | 1.44x | KR#1,692/2,405 Sec#99/231 |
| EV/EBITDA | 12.02x | KR#781/2,405 Sec#42/231 |
| FCF Yield | 3.61% | KR#966/2,405 Sec#60/231 |
| Profitability | ||
| ROE | 25.09% | KR#100/2,405 Sec#7/231 |
| ROA | 16.51% | KR#87/2,405 Sec#8/231 |
| Op. Margin | 12.51% | KR#390/2,405 Sec#34/231 |
| Revenue Growth | -2.68% | KR#1,658/2,405 Sec#161/231 |
| Earnings Growth | -27.51% | KR#967/2,405 Sec#62/231 |
| Financial Health | ||
| Debt Ratio | 51.98% | KR#979/2,405 Sec#116/231 |
| Total Debt | 4.70B KRW | KR#1,794/2,405 Sec#173/231 |
| FCF | 4.44B KRW | KR#935/2,405 Sec#65/231 |
| Cash | 128.6M KRW | KR#2,369/2,405 Sec#228/231 |
| Current Ratio | 1.55x | KR#1,149/2,405 Sec#126/231 |
| Net Debt/EBITDA | 0.43x | KR#658/2,405 Sec#39/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | 68.47% | KR#125/2,405 Sec#5/231 |
| 1M Return | -26.48% | KR#2,074/2,405 Sec#203/231 |
| From 52W High | -49.71% | KR#1,091/2,405 Sec#80/231 |
| 1Y MDD | -55.68% | KR#1,201/2,405 Sec#99/231 |
| Trading | ||
| Volume | 688,762 shares | KR#123/2,405 Sec#6/231 |
| Trading Value | 1.52B KRW | KR#513/2,405 Sec#52/231 |
| Foreign Own. | 1.54% | KR#1,806/2,405 Sec#178/231 |
| Per Share | ||
| EPS | 182 KRW | KR#1,312/2,405 Sec#87/231 |
| BPS | 727 KRW | KR#2,344/2,405 Sec#221/231 |
Company Info
Established in 1975, the company was listed on KOSDAQ in 2003 and rebranded as JW Shin Yak in 2016 after absorbing the former Joongwae Shin Yak in 2009. It manufactures and sells specialized pharmaceuticals, including antifungals and urological agents, serving the dermatology, urology, pediatrics, and internal medicine markets. JW Shin Yak is developing CAR-NK therapies using macrophage gene manipulation technology to enter the next-generation anti-cancer market and expand into the hair loss and cosmeceutical sectors. The company is headquartered in Gwacheon, Gyeonggi Province.